Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Cognitive Correlates of Antidepressant Treatment Response in Elders

This study has been completed.
Information provided by:
St. Michael's Hospital, Toronto Identifier:
First received: June 9, 2009
Last updated: November 18, 2011
Last verified: May 2011
Major depression is a very common health problem affecting older persons. The present standard of treatment is with medications called "antidepressants". Antidepressants have been studied extensively in older persons with normal brain function and have been shown to be effective. However, certain types of brain dysfunction called "executive impairment" (inability to do higher order thinking) may lead to poor treatment outcomes. This study will compare how older depressed people with different levels of executive impairment respond differently to standard antidepressant treatment. Knowing this information will lead to more rational targeting of available treatments, leading to improved treatment outcomes.

Condition Intervention Phase
Drug: Zoloft (antidepressant)
Phase 4

Study Type: Interventional
Study Design: Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Determining the Impact of Dementia and Executive Impairment on Antidepressant Treatment Response in Older Persons

Resource links provided by NLM:

Further study details as provided by St. Michael's Hospital, Toronto:

Primary Outcome Measures:
  • depression [ Time Frame: June 1, 2007 - June 1, 2008 ] [ Designated as safety issue: No ]

Enrollment: 30
Study Start Date: June 2007
Study Completion Date: October 2009
Primary Completion Date: April 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Both arms of the study will include zoloft. However, the treatment response to zoloft will be compared in two different subgroups.
Drug: Zoloft (antidepressant)
Zoloft 50-200 mg po od x 12 weeks
Other Name: Sertraline


Ages Eligible for Study:   65 Years to 90 Years   (Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • above the age of 65,
  • speak English fluently,
  • experience depression, AND
  • not yet on active treatment.

Exclusion Criteria:

  • active delirium,
  • substance abuse,
  • mental illness other than major depression,
  • active CNS disease,
  • unstable systematic medical disease, OR
  • current of past psychotic disorder.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01477268

Canada, Ontario
St Michael's Hospital
Toronto, Ontario, Canada, M5B 1W8
Sponsors and Collaborators
St. Michael's Hospital, Toronto
Principal Investigator: Corinne Fischer, MD St. Michaels Hospital
  More Information

Responsible Party: Dr. Corinne E. Fischer, St. Michael's Hospital Identifier: NCT01477268     History of Changes
Other Study ID Numbers: 06-296 
Study First Received: June 9, 2009
Last Updated: November 18, 2011
Health Authority: Canada: Ethics Review Committee

Keywords provided by St. Michael's Hospital, Toronto:

Additional relevant MeSH terms:
Behavioral Symptoms
Antidepressive Agents
Psychotropic Drugs
Serotonin Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Serotonin Agents
Physiological Effects of Drugs processed this record on October 21, 2016